Please login to the form below

Not currently logged in

Bamboo Therapeutics

This page shows the latest Bamboo Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Pfizer goes big on gene therapy with $500m facility spend

Pfizer goes big on gene therapy with $500m facility spend

Pfizer also added to its stable with the $700m acquisition of gene therapy specialist  Bamboo Therapeutics, which added an rAAV platform as well as candidates for giant axonal neuropathy and Duchenne ... It also took a 15% stake in  Vivet Therapeutics

Latest news

  • Catalent preps for complex therapy boom with $1.2bn Paragon buy Catalent preps for complex therapy boom with $1.2bn Paragon buy

    Last month, Pfizer paid around $640m for a 15% stake in Vivet Therapeutics, while Biogen snapped up Nightstar Therapeutics for $800m and Roche acquired Spark Therapeutics in February for $4.3bn. ... And in 2018, Novartis’ bought AveXis for $8.7bn to

  • Pfizer abandons antibody for Duchenne Pfizer abandons antibody for Duchenne

    News of the setback spurred modest gains in the share price of Sarepta, which sells exon-skipping therapy Exondys 51 (eteplirsen) in the US and Europe, as well as PTC Therapeutics ... Pfizer still has an iron in the DMD fire, in the form of its Bamboo

  • Pfizer buys gene therapy specialist Bamboo Pfizer buys gene therapy specialist Bamboo

    Pfizer has made a play for a larger chunk of the emerging gene therapy market, agreeing a $700m deal to acquire Bamboo Therapeutics. ... Another $495m will go to Bamboo's investors if its gene therapy programmes make it through development and onto the

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    $14bn, antibiotic business interests from AstraZeneca for $1.4bn and Bamboo Therapeutics for $645m. ... 690. Bamboo Therapeutics (US). Pfizer (US). Company acquisition. Preclinical gene therapies and manufacturing plant.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....